Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura.
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2014
At a glance
- Drugs NXN 188 (Primary)
- Indications Migraine without aura
- Focus Therapeutic Use
- Sponsors NeurAxon
- 01 Nov 2010 Primary endpoint 'Headache severity' has not been met.
- 01 Nov 2010 Results were reported in a NeuAxon media release.
- 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History